Les anticoagulants oraux directs dans la maladie coronaire

Task Force, 2013, 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology, Eur Heart J, 34, 2949, 10.1093/eurheartj/eht296 Roffi, 2016, Eur Heart J, 37, 267, 10.1093/eurheartj/ehv320 Oldgren, 2011, Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial, Eur Heart J, 32, 2781, 10.1093/eurheartj/ehr113 Alexander, 2011, Apixaban with antiplatelet therapy after acute coronary syndrome, N Engl J Med, 365, 699, 10.1056/NEJMoa1105819 Alexander, 2014, Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial, Eur Heart J, 35, 224, 10.1093/eurheartj/eht445 Mega, 2009, Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial, Lancet, 374, 29, 10.1016/S0140-6736(09)60738-8 Mega, 2012, Rivaroxaban in patients with a recent acute coronary syndrome, N Engl J Med, 366, 9, 10.1056/NEJMoa1112277 Ohman, 2017, Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial, Lancet, 389, 1799, 10.1016/S0140-6736(17)30751-1 Wiviott, 2007, Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 357, 2001, 10.1056/NEJMoa0706482 Gibson, 2016, Prevention of bleeding in patients with atrial fibrillation undergoing PCI, N Engl J Med, 375, 2423, 10.1056/NEJMoa1611594